Both the rituximab dose and maintenance immunosuppression in steroid-dependent/ frequently-relapsing nephrotic syndrome have important effects on outcomes
Kidney International Nov 13, 2019
Chan EYH, Webb H, Yu E, et al. - Researchers undertook this international, multicenter retrospective analysis to define the optimal rituximab regimen to treat steroid-dependent/ frequently-relapsing nephrotic syndrome (SDFRNS) in children. This investigation was performed among children 1-18 years of age with complicated SDFRNS taking rituximab between 2005-2016 for 18 or more months follow-up, at 11 tertiary pediatric nephrology centers in Asia, Europe and North America. They evaluated the influence of rituximab prescribed at three dosing levels: low (375mg/m2), medium (750mg/m2) and high (1125-1500mg/m2), with or without maintenance immunosuppression. Overall 511 children (median age 11.5 year, 67% boys) were included, of those, low, medium and high dose rituximab was received by 191, 208 and 112, respectively. Maintenance immunosuppression was received by 283 (55%). Findings revealed the shortest relapse-free survival among children receiving low-dose rituximab without maintenance immunosuppression. Therefore, treatment outcomes are significantly influenced by both rituximab dose and maintenance immunosuppression.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries